NASOPHARYNGITIS is the #12 most commonly reported adverse reaction for Cosentyx, manufactured by Novartis Pharmaceuticals Corporation. There are 7,647 FDA adverse event reports linking Cosentyx to NASOPHARYNGITIS. This represents approximately 1.5% of all 494,338 adverse event reports for this drug.
Patients taking Cosentyx who experience nasopharyngitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
NASOPHARYNGITIS7,647 of 494,338 reports
NASOPHARYNGITIS is a less commonly reported adverse event for Cosentyx, but still significant enough to appear in the safety profile.
Other Side Effects of Cosentyx
In addition to nasopharyngitis, the following adverse reactions have been reported for Cosentyx:
NASOPHARYNGITIS has been reported as an adverse event in 7,647 FDA reports for Cosentyx. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is NASOPHARYNGITIS with Cosentyx?
NASOPHARYNGITIS accounts for approximately 1.5% of all adverse event reports for Cosentyx, making it a notable side effect.
What should I do if I experience NASOPHARYNGITIS while taking Cosentyx?
If you experience nasopharyngitis while taking Cosentyx, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.